Metaplastic breast cancer (BC-Mp) presents diagnostic and therapeutic complexities, with scant literature available. Correct assessment of tumor size by ultrasound (US) and full-field digital mammography (FFDM) is crucial for treatment planning. Methods: A retrospective cohort study was conducted on databases encompassing records of BC patients (2012–2022) at the National Research Institutes of Oncology (Warsaw, Gliwice and Krakow Branches). Inclusion criteria comprised confirmed diagnosis in postsurgical pathology reports with tumor size details (pT) and availability of tumor size from preoperative US and/or FFDM. Patients subjected to neoadjuvant systemic treatment were excluded. Demographics and clinicopathological data were gathered. Results: Forty-five females were included. A total of 86.7% were triple-negative. The median age was 66 years (range: 33–89). The median pT was 41.63 mm (6–130), and eight patients were N-positive. Median tumor size assessed by US and FFDM was 31.81 mm (9–100) and 34.14 mm (0–120), respectively. Neither technique demonstrated superiority (p> 0.05), but they both underestimated the tumor size (p= 0.002 for US andp= 0.018 for FFDM). Smaller tumors (pT1-2) were statistically more accurately assessed by any technique (p< 0.001). Only pT correlated with overall survival. Conclusion: The risk of underestimation in tumor size assessment with US and FFDM has to be taken into consideration while planning surgical procedures for BC-Mp.
化生性乳腺癌（BC-Mp）的诊断与治疗具有复杂性，现有文献资料较为有限。通过超声（US）和全视野数字化乳腺X线摄影（FFDM）准确评估肿瘤大小对制定治疗方案至关重要。方法：本研究基于国家肿瘤研究所（华沙、格利维采及克拉科夫分院）2012至2022年间乳腺癌患者数据库开展回顾性队列研究。纳入标准包括术后病理报告确诊且包含肿瘤大小（pT）信息，同时具备术前US和/或FFDM测量的肿瘤尺寸数据。接受新辅助全身治疗的患者被排除。研究收集了人口统计学及临床病理学资料。结果：共纳入45例女性患者，其中86.7%为三阴性乳腺癌。中位年龄66岁（范围：33-89岁）。中位pT为41.63毫米（范围：6-130毫米），8例患者淋巴结阳性。US和FFDM评估的肿瘤中位尺寸分别为31.81毫米（范围：9-100毫米）和34.14毫米（范围：0-120毫米）。两种影像学技术均未显示显著优势（p>0.05），但均存在肿瘤尺寸低估现象（US：p=0.002；FFDM：p=0.018）。对于较小肿瘤（pT1-2期），任何技术评估的准确性均显著更高（p<0.001）。仅pT与总生存期存在相关性。结论：在制定BC-Mp手术方案时，必须充分考虑US和FFDM评估肿瘤尺寸可能存在的低估风险。
肿瘤(癌症)患者之家